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Abstract
As the defining feature of Acute Myeloid Leukemia (AML) is a maturation arrest, a highly desirable therapeutic strategy is to
induce leukemic cell maturation. This therapeutic strategy has the potential of avoiding the significant side effects that
occur with the traditional AML therapeutics. We identified a natural compound securinine, as a leukemia differentiation-
inducing agent. Securinine is a plant-derived alkaloid that has previously been used clinically as a therapeutic for primarily
neurological related diseases. Securinine induces monocytic differentiation of a wide range of myeloid leukemia cell lines as
well as primary leukemic patient samples. Securinine’s clinical potential for AML can be seen from its ability to induce
significant growth arrest in cell lines and patient samples as well as its activity in significantly impairing the growth of AML
tumors in nude mice. In addition, securinine can synergize with currently employed agents such as ATRA and decitabine to
induce differentiation. This study has revealed securinine induces differentiation through the activation of DNA damage
signaling. Securinine is a promising new monocytic differentiation inducing agent for AML that has seen previous clinical
use for non-related disorders.
Citation: Gupta K, Chakrabarti A, Rana S, Ramdeo R, Roth BL, et al. (2011) Securinine, a Myeloid Differentiation Agent with Therapeutic Potential for AML. PLoS
ONE 6(6): e21203. doi:10.1371/journal.pone.0021203
Editor: John D. Minna, University of Texas Southwestern Medical Center at Dallas, United States of America
Received January 14, 2011; Accepted May 23, 2011; Published June 24, 2011
Copyright:  2011 Gupta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for this work was received from National Institutes of Health grant R43 CA134089 and Children’s Leukemia Research Foundation
(childrensleukemia.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The author has read the journal’s policy and has the following conflicts: David Wald, a former employee, and Mukesh Agarwal, a current
employee of Invenio Therapeutics, both have an equity interest in Invenio Therapeutics, which previously had an option to license agreement for intellectual
property that included securinine. This agreement is now expired. David Wald is listed as an inventor on a patent application submitted by Case Western Reserve
University related to securinine, the details of which are: Patent Application No. 60/943,415 entitled, ‘‘Myeloid Differentiation Inducing Agents.’’ Case Western
Reserve University has 100% ownership of this intellectual property as the discovery was made at their institution. There are no products in development or
marketed products to declare. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. The authors do not currently have any
other declarations.
* E-mail: agarwamukesh@yahoo.com (MKA); dnw@case.edu (DNW)
Introduction
Acute myeloid leukemia (AML) is the most common type of acute
leukemia with over 13,000 cases expected in the United States this
year, mostly in older adults [1,2]. The current therapeutic regimen
for AML involves traditional chemotherapeutics which unfortunate-
ly have poor efficacy and high toxicity. This is especially problematic
in elderly patients as they are not able to tolerate the existing
chemotherapeutic agents and they are left with no satisfactory
therapeutic options. Currently the 5 year survival in the over 65 age
group is only 4% while it is 33% for those under 65 [2,3].
AML is a broad range of disorders that all have the defining
feature of leukemic cells with a maturation arrest. The poor
efficacy of the current AML therapeutics is likely due to the
pathophysiology of AML as it is characterized by both the arrest of
differentiation of immature myeloid cells as well as rapidly dividing
cells. Unfortunately, the current AML chemotherapeutics such as
cytarabine and idarubicin primarily target the highly proliferative
cells. By instead inducing terminal differentiation, leukemic cells
can be forced to lose their ability to proliferate and eventually die
off without the necessity for overt cytotoxicty.
The clinical potential of differentiation therapy for AML has
been demonstrated for one rare subtype of AML, acute
promyelocytic leukemia (APL) (5–10% of AML). In this case the
differentiation-inducing agent all-trans retinoic acid (ATRA) has
revolutionized the treatment of APL and leads to the long term
survival and presumed cure of 75–85% of patients [4]. In addition
as ATRA is more tolerable for elderly patients, this group can still
achieve good outcomes with regimens consisting of ATRA and
low dose chemotherapy. Unfortunately ATRA is not clinically
useful for other subtypes of AML. Through a compound library
screen performed to identify new AML differentiation-inducing
compounds, we discovered a plant derived compound, securinine,
which exhibits potent leukemia differentiation-inducing activity.
Securinine is the major alkaloid natural product from the root of
the plant securinega suffruticosa. It was originally discovered over 50
years ago and reported to have potent biological activity [5].
Though this compound has not been utilized in the United States,
it has been used clinically in several other countries particularly
China and Russia. In China it is considered one of the 50
fundamental Chinese herbs and is used in Chinese herbal
medicine [6]. Securinine has been found to be active as a c-
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amino butyric acid (GABA) receptor antagonist [7]. Its activity as a
GABA antagonist, likely explains its reported clinical success in
limited studies for the treatment of neurological conditions such as
amyotrophic lateral sclerosis (ALS), poliomyelitis and multiple
sclerosis [8,9,10]. Though securinine has never been previously
tested clinically as an anti-cancer agent, there is a single report that
demonstrates that it can induce apoptosis at high doses in a
leukemic cell line [11]. In addition, we have recently found that
securinine may have potential utility against certain types of colon
cancer [12]. Finally, securinine has also been reported to induce
macrophage activation and therefore proposed as a potential
therapeutic for infectious processes [13]. Here we demonstrate
that securinine can induce AML differentiation and has potential
as an AML therapeutic.
Results
Discovery of Securinine
In order to identify clinically useful differentiation-inducing
agents, a small molecule compound library screen was performed
using a collection consisting predominantly of drugs that have
previously been used in humans (Prestwick and Lopac collection).
The phenotypic screen assessed differentiation by measuring the
functional maturation of HL-60 leukemic cells by the nitroblue
tetrazolium (NBT) reduction assay, a test that is highly specific to
and has been used extensively as a measure of functional
myelomonocytic differentiation [14,15,16,17,18]. The NBT re-
duction test measures the ability of cells to generate a respiratory
burst, a function that is only present in differentiated cells. As only
live cells reduce NBT, this screen is heavily biased in identifying
potent, yet non-toxic agents. Specific details regarding the screen
and the ‘‘hits’’ resulting from this screen have been described
previously [19]. From this screen securinine was identified as the
most potent inducer of differentiation. Interestingly, securinine
was also identified as a strong ‘‘hit’’ during later screening efforts
utilizing the NCI diversity set. Securinine, an alkaloid with a
unique ring structure, is structurally unrelated to any previously
reported myeloid differentiation inducers, but interestingly it has
seen clinical use for non-cancer related conditions (figure 1a).
Securinine induces AML differentiation
Securinine exhibits clinical potential as an AML differentiation
agent partially due to its ability to differentiate a wide variety of
AML cell lines as well as patient samples. To confirm securinine
induces AML differentiation, three AML cell lines were investi-
gated, HL-60 cells that typically undergo granulocytic or
monocytic differentiation and THP-1 and OCI-AML3 cells that
undergo monocytic differentiation. These cell lines were examined
by morphology, immunophenotyping, and NBT reduction
(figure 1b–d). Morphologically, securinine induces monocytic
differentiation as can be seen from an increased cytoplasmic to
nuclear ratio. In addition, HL-60 cells exhibit a condensed and
indented nucleus while THP-1 cells become significantly larger in
size (figure 1b). No significant morphologic changes were observed
with OCI-AML3 cells, likely as they already have a predominant
monocytic morphology.
Immunophenotyping was performed to confirm monocytic
differentiation in HL-60 cells as this cell line, unlike THP-1 and
OCI-AML3 cells, differentiates along several different pathways.
This analysis confirmed monocytic differentiation as securinine
treatment leads to the upregulation of the cell surface markers
CD11b, which is upregulated during myelomonocytic differenti-
ation, as well as CD14 which is upregulated primarily during
monocytic differentiation. In comparison, ATRA which induces
granulocytic differentiation induces primarily CD11b expression
while vitamin D3 which induces monocytic differentiation
upregulates both CD11b and CD14 (figure 1c). Similarly, in
THP-1 and OCI-AML3 cells which only undergo monocytic
differentiation, maturation was confirmed by CD11b expression
that increased from 11% to 73% and 15% to 64% respectively
after 96 hours of securinine treatment (15 mM). Besides, morphol-
ogy and immunophenotyping, securinine exhibits high differenti-
ation activity in HL-60, OCI-AML3, and THP-1 cells as
measured by NBT reduction. For example, securinine leads to
NBT reduction in 90%+/25 of HL-60 cells and 89%+/23 of
THP-1 cells (figure 1d).
Confirmation of Securinine-mediated differentiation
In order to begin to elucidate pathways through which
securinine induces AML differentiation, a gene expression
microarray experiment was performed to identify gene expression
changes in HL-60 cells after securinine treatment. As the
differentiation process itself leads to changes in the expression of
thousands of genes which help define the phenotype of the
differentiated cells, but fail to give significant insights into
securinine’s mechanisms of action, our initial analysis of this data
was focused on genes with a known function in transcription. This
analysis identified 158 genes whose expression level was
modulated at least 2.5 fold in response to securinine treatment
(24 hours) as compared to vehicle treated cells (see Figure S2).
Many of these genes include transcription factors that are well
known to modulate AML differentiation such as c-myc and c-myb
which are downregulated and CEBP/b, CEBP/d, egr-1, mafB,
fos, and jun that are upregulated. These findings further support
securinine induces myeloid differentiation.
In order to validate the gene array results, the upregulation of
the myeloid transcription factor, CEBP/b, and downregulation of
proliferation related gene c-myc and transcription factor c-myb
were analyzed by real-time PCR. As can be seen in figure 1e, the
securinine-mediated upregulation of CEBP/b and downregulation
of c-myc and c-myb were confirmed.
Securinine induces terminal differentiation
To gain a better understanding of securinine’s activity on
leukemic cells, its effects on leukemic cell growth of HL-60, THP-
1, and OCI-AML3 cells were investigated. Securinine led to a
significant inhibition of cell growth in all cell lines as compared to
the vehicle control (figure 2a). For example, in THP-1 cells at 5
days after treatment securinine led to only 22%+/22.6 of the
proliferation seen in vehicle treated cells (figure 2a). In order to
further understand how securinine induces growth inhibition,
cell cycle analysis was performed. Though securinine leads to
significant alterations in the cell cycle, the specific alterations are
cell type specific. Securinine growth inhibition of HL-60 cells
involves an accumulation of cells in the G0/G1 phase of the cell
cycle with 65% of cells present in G0/G1 as compared to 47% in
the vehicle control at 24 hours after treatment (figure 2b).
Consistent with accumulation in the G0/G1 phase, securinine
induces p21 that is known to play an important role in preventing
the G1 to S transition (figure 2c). In contrast to HL-60 and OCI-
AML3 cells, in THP-1 cells, securinine leads predominantly to
accumulation of cells in the G2/M phase with 41% in the
securinine treated cells as compared to 14% present in vehicle
treated cells after 24 hours of treatment.
Securinine induces dramatic growth inhibition
Though securinine induces evidence of differentiation, for
differentiation agents to be clinically useful they must lead to
Securinine Induces AML Differentiation
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Figure 1. Securinine induces monocytic differentiation of AML cells. A. Chemical structure of Securinine and ATRA. B. Securinine induces
morphologic changes consistent with monocytic differentiation. After treatment for 4 days with securinine (15 mM), cytospin preparations were
prepared and HL-60 and THP-1 cells were stained with Wright-Giemsa stain. C. Securinine induces immunophenotypic changes consistent with
monocytic differentiation. After treatment for 4 days with securinine (15 mM), HL-60 cells were stained with CD11b-PE and CD14-FITC, THP-1 and OCI-
AML3 cells were stained with CD11b-PE and flow cytometric analysis was performed. D. Securinine induces potent NBT reduction activity consistent
with myelomonocytic differentiation. HL-60, OCI-AML3 and THP-1 cells were treated with securinine (15 mM) or ATRA (1 mM) for 4 days and then the
NBT reduction assay was performed by stimulating cells with 200 ng/ml of PMA in the presence of 5 mg/ml NBT for 20 minutes. The percentage of
NBT positive cells (blue cells) was calculated by counting at least 200 cells under a light microscope. E. Securinine regulates the expression of
transcription factors with known roles in AML differentiation. HL-60 cells were treated with securinine (15 mM) or vehicle for 24 hours and the relative
expression of the indicated genes was measured by real-time PCR.
doi:10.1371/journal.pone.0021203.g001
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significant growth arrest. Further this growth inhibition must result
in viable cells maintaining a loss of proliferative capacity even
when drug is washed off. To assess whether the observed
securinine-mediated growth inhibition and differentiation results
in terminal differentiation, colony forming assays were performed
in soft agar. Limited exposure (96 hours) of THP-1 and HL-60
(and to a lesser extent OCI-AML3 cells) to securinine at doses
greater than 10 mM led to dramatic reductions in colony
formation in soft agar demonstrating that terminal differentiation
is induced (figure 2d). In contrast to the significant inhibition of
colony formation in AML cells, treatment with securinine did not
lead to a significant change in the growth of colonies from normal
Figure 2. Securinine leads to alterations in AML cell proliferation. A. Securinine inhibits AML cell proliferation. HL-60, OCI-AML3 and THP-1
cells were treated with vehicle or securinine (15 mM) for 5 days. The number of cells present at days 1, 3, 5 after treatment was determined by
counting at least 200 cells with a hematocytometer. Results are expressed as percentage of cells present in the treated as compared to vehicle wells.
Results are an average of 3 independent experiments. B. Securinine induces alterations in the cell cycle of HL-60, OCI-AML3 and THP-1 cells. AML cells
were treated for 24 hours with the securinine (15 mM) or vehicle, fixed, stained with propidium iodide and analyzed for cell cycle content by flow
cytometry. Results are representative of 3 independent experiments. C. Securinine induces p21. HL-60 cells were treated with securinine (15 mM) for
the indicated timepoints and cell lysates were analyzed for p21 expression by western blot. D. Securinine potently inhibits colony formation of AML,
but not normal hematopoietic cells. HL-60, OCI-AML3 and THP-1 cells were incubated with securinine or vehicle for 4 days and the drug was washed
off. An equal number of viable cells were added to soft agar and colony formation was assessed after 10 days. Normal human bone marrow was
treated in a similar manner, but was plated in methylcellulose. Results are expressed as the percentage of colonies in the treated group compared to
vehicle control group and are an average of two independent experiments performed in duplicate.
doi:10.1371/journal.pone.0021203.g002
Securinine Induces AML Differentiation
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human bone marrow (figure 2d). In addition, it did not appear
to affect the differentiation of normal human bone marrow
progenitor cells along the myeloid or erythroid lineages. As
expected, securinine did not lead to any significant difference in
cell death at the doses utilized as compared to vehicle treated cells.
Securinine induces differentiation in a wide range of AML
cell lines and primary patient samples
Besides HL-60, OCI-AML3, and THP-1 cells, one of the most
promising properties of securinine is its ability to differentiate a
wide variety of AML cell lines and patient samples. For example,
securinine induces evidence of differentiation in NB4, U937,
NOMO-1, and MV-411 cells (figure 3a). In addition securinine
can also induce evidence of differentiation in primary patient
leukemic samples (figure 3b). Securinine induced differentiation in
4 out of 6 leukemia patient samples tested as measured by NBT
reduction. In one of the two patient samples that did not exhibit
securinine-mediated differentiation, the cells instead underwent
securinine-mediated cell death. Interestingly, securinine was able
to induce differentiation in cells from a patient with chronic
myeloid leukemia indicating that it may also be useful for this
closely related myeloid disorder. Several AML samples were also
tested for the induction of growth inhibition by colony assays and
securinine was found to significantly reduce the ability of primary
AML cells to form colonies in 3 out of the 4 patient samples tested
(figure 3c).
Securinine synergizes with other agents with potential
clinical use for AML
Though ATRA is a successful differentiation agent for a subset
of AML patients, it is only clinically efficacious when combined
with low dose chemotherapy. Therefore, we investigated combi-
nation therapies of securinine with other clinically used agents.
Securinine can synergize with several other differentiation-
inducing agents including ATRA, vitamin D, and decitabine
suggesting that these agents may work through different pathways
and raising the possibility that securinine may be useful as part of
a combination therapy (figure 3d). Co-treatment of HL-60 cells
with a low dose of securinine (2 mM) led to an increase in NBT
reduction from 6–8% with securinine alone to 91% with ATRA
(100 nM), 84% with decitabine (100 ng/ml) and 98% with 1,25
dihydroxyvitamin D3 (50 nM). Similar results were obtained using
other AML cell lines (data not shown). This work raises the
possibility that securinine may enhance the clinical activity of
ATRA and decitabine as well as potentially allow the use of levels
of Vitamin D3 that do not cause toxic hypercalcemia.
Securinine exhibits low in vitro toxicity
In order for securinine to be clinically useful for AML, it must
induce preferential effects on AML cells. Utilizing a panel of
normal and cancer cells, AML differentiation occurs at several fold
lower doses (10–15 mM) than the LD50 doses at three days after
treatment in the other cell types tested (45–60 mM) (figure 3e). In
addition, as mentioned previously, securinine did not significantly
impair the growth of colonies from normal bone marrow.
Securinine demonstrates in vivo activity
In order to assess securinine’s potential as an AML therapeutic,
mouse xenograft experiments were performed. For these exper-
iments, the effect of securinine on inhibiting the growth of
established HL-60 cell subcutaneous tumors in nude mice was
assessed. In this tumor model, tumor growth was significantly
impaired with securinine treatment indicating it has potential as an
AML therapeutic (figure 4). Securinine treated mice (n = 5 mice,
bilateral tumors), exhibited an average of more than 75% smaller
tumors than vehicle treated mice at the end of the study period.
Due to the extremely short half life of securinine (estimated to be
significantly less than 30 minutes), these experiments utilized
frequent securinine administration (3 times a day) to show efficacy.
A second study performed using 2 times a day dosing showed
similar results (70% smaller tumors at the end of the study period).
Initial experiments performed with once a day administration did
not show a statistically significant effect on tumor growth. Though
we utilized frequent dosing of securinine, we did not observe any
evidence of mouse toxicity (including seizures) or weight loss.
Securinine-mediated differentiation does not involve
GABA receptor inhibition
As securinine’s clinical use for neurological diseases is based
upon its well known function as a GABA receptor antagonist and
leukemic cells (including HL-60 cells) are known to express this
receptor, we assessed whether or not this activity plays a role in
securinine-mediated differentiation [20]. Other GABA antagonists
such as picrotoxin, bicuculline, and flumazenil do not exhibit
differentiation-inducing activity in HL-60 cells suggesting that
securinine is likely working through a different mechanism (data
not shown). In addition, virosecurinine and allosecurinine which
are stereoisomers of securinine that do not exhibit as high an
affinity for the GABA receptor as securinine were found to induce
relatively similar differentiation of HL-60 cells [7,21,22]. For
example, allosecurinine (15 mM) and virosecurinine (15 mM)
induced differentiation in HL-60 cells with allosecurinine differ-
entiating 80% and virosecurinine 95% of cells as measured by the
NBT reduction test. As securinine’s interaction with the GABA
receptor is responsible for its main clinical side effect, seizures, it is
quite likely that this molecule can be modified to maintain AML
differentiation activity while minimizing its seizure effects.
Securinine induces DNA damage signaling
In order to further assess how securinine leads to differentiation,
we investigated its effects on DNA damage signaling as we
previously observed securinine induces weak DNA damage in
colon cancer cells [23]. Interestingly, even though non-cytotoxic
doses of securinine were utilized, securinine induced limited DNA
damage and the subsequent activation of DNA damage signaling
in leukemic cells (figure 5). While the activation of DNA damage
signaling is well known to lead to growth arrest as a protective
response in many cell types, many pathways involved in this
response overlap with AML differentiation mechanisms. For
example, p53 and p21 have both been associated with growth
arrest and AML differentiation [24,25]. After treatment of AML
cells with securinine, we observed limited DNA damage (as
measured by H2AX phosphorylation) and the activation of DNA
damage signaling (as measured by Chk1 phosphorylation and the
induction of p53 and p21) (figure 5a).
Inhibition of DNA damage signaling impairs securinine-
mediated differentiation
Upon disruption of DNA damage signaling with chemical
inhibitors or the knockdown of Chk1 using shRNA, securinine-
mediated (but not ATRA-mediated) differentiation is greatly
attenuated (figure 5b). For example, pre-treatment of OCI-
AML3 cells with caffeine (ATM/ATR inhibitor) or with UNC-
01 (Chk1/2 inhibitor) significantly impaired securinine-mediated
differentiation. In addition the knockdown of Chk1, led to a
significant decrease in securinine mediated, but not ATRA
Securinine Induces AML Differentiation
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Figure 3. Securinine has differentiation activity in multiple AML cell lines and patient samples and can synergize with clinically
used therapeutics. A. Securinine induces differentiation in multiple leukemic cell lines. The indicated cell lines were treated with vehicle, securinine
(15 mM) or ATRA (1 mM) for 4 days and the NBT reduction assay was performed. Results are representative of 3 independent experiments. B.
Securinine can induce differentiation in primary patient samples. Primary leukemic blasts derived from the peripheral blood of patients with active
leukemia disease were purified by flow sorting after staining with CD34-PE if the leukemic blast percentage was less than 70%. Cells were treated
with securinine (15 mM) or vehicle for up to 6 days and assessed for differentiation by NBT reduction. AML subtype is indicated in the figure. C.
Securinine can induce significant growth inhibition in primary patient samples. Primary leukemic blasts were treated for 5 days with securinine, the
Securinine Induces AML Differentiation
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mediated-differentiation as measured by CD11b expression and
NBT reduction (figure 5b). In contrast, despite the nearly complete
knockdown of p53 expression in OCI-AML3 cells, there was no
impairment in securinine-mediated differentiation. Of note HL-60
cells, which are p53-null, are highly susceptible to securinine-
mediated differentiation suggesting that securinine differentiation
is independent of p53.
p21 is important for securnine-mediated growth
inhibition, but not differentiation
As p21 is known to play an important role in both growth
inhibition and differentiation, the role of p21 in mediating
securinine’s biological effects was analyzed. In order to assess the
importance of p21 in securinine’s activities, p21 was knocked
down using lentiviral shRNA in OCI-AML3 cells. Surprisingly, as
can be seen from figure 5c, knockdown of p21 had no effect on
securinine-mediated differentiation. In contrast, p21 deficiency
impairs securinine-mediated growth inhibition suggesting it plays a
role in securinine-mediated growth inhibition, but not differenti-
ation.
Discussion
We have identified a promising new AML differentiation agent,
securinine, through a compound library screen. Securinine is a
plant-derived alkaloid that has already seen clinical use for
primarily neurological conditions. Due to its prior clinical use and
its ability to differentiate a wide range of AML cell lines as well
as patient samples, securinine is a promising new therapeutic
candidate for AML.
New therapeutics for AML that are efficacious for even a small
subset of patients are highly desirable due to the poor efficacy and
high toxicity of the existing AML chemotherapeutics that have not
undergone significant change over the last 30 years. The potential
of AML differentiation agents has been demonstrated through the
use of ATRA that has seen remarkable clinical success for a small
number of AML patients that have the Acute Promyelocytic
Leukemia (APL) subtype. Unfortunately ATRA is not efficacious
for the majority of AML patients that fall into the other AML
subtypes. Securinine’s ability to enhance ATRA-mediated differ-
entiation particularly in non-APL cell lines leads to the possibility
that it may allow ATRA to be used for a wider subset of patients.
In addition securinine can synergize with other agents such as
decitabine that alone induces weak differentiation as well as
vitamin D which though a potent differentiation compound leads
to toxic hypercalcemia at the doses required for its activity as a
single agent. Securinine’s ability to synergize with several agents
likely relates the fact that it induces differentiation through a
different mechanism.
Our studies suggest that the mechanism of securinine-mediated
differentiation involves limited DNA damage that leads to the
activation of DNA damage signaling. As DNA damage signaling is
intended as a protective response, it can lead to growth arrest or
cell death dependent upon the amount of damage and the specific
cell type. As leukemia cells have a propensity to differentiate, these
cells can undergo differentiation after limited DNA damage in
addition to growth arrest. Securinine-mediated differentiation was
found to be dependent upon an ATM/ATR and Chk1, but
independent of p53 and p21. Interestingly, we found that p21 was
important for securinine-mediated growth inhibition, but not
differentiation suggesting a bifurcation of the AML differentiation
response in the DNA damage signaling pathway upstream of p21.
Securinine exhibits in vivo activity as demonstrated through an
AML mouse xenograft model system with no evidence of toxicity
at the doses utilized. In previous clinical studies investigating
securinine’s potential for neurological diseases, the primary side
effect reported was seizures due its known activity as a GABAA
receptor inhibitor which is thought to be important for its efficacy.
Figure 4. Securinine significantly inhibits the growth of established AML tumors in nude mice. Results shown represent the average
volume of tumors from the mice measured during the study period. * p = 0.0075; ** p = 0.046; *** p,0.001.
doi:10.1371/journal.pone.0021203.g004
drug was washed off and the cells were plated in methylcelluose and assessed for colony formation after 10 days. AML subtype is indicated in the
figure. D. Securinine can synergize in HL-60 cells with Vitamin D3, ATRA, and Decitabine. To assess Vitamin D3, ATRA and decitabine synergy, HL-60
cells were treated with the indicated compounds for 4 days and the NBT reduction assay was performed. Results are representative of 3 independent
experiments. E. Securinine exhibits low in vitro toxicity. The indicated cell lines were treated with up to 100 mm of securinine for 3 days and cell death
was assessed. Results represent three independent experiments.
doi:10.1371/journal.pone.0021203.g003
Securinine Induces AML Differentiation
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Figure 5. Mechanisms of securnine-mediated differentiation. A. Securinine activates DNA damage signaling. OCI-AML3 cells were treated
with securinine (15 mM) for the indicated times and cell lysate was prepared. The lyaste was analyzed for the proteins shown by western blot. B.
Inhibition of DNA damage signaling significantly impairs securinine-mediated differentiation. First panel: OCI-AML3 cells were treated with UCN-01
(1 mM), caffeine (1 mM), securinine (15 mM), or a combination for 4 days and the NBT reduction assay was performed. Results are an average of 3
experiments. Second Panel: OCI-AML3 cells stably infected with shp53, shChk1, shp21, or a vector control were treated with securinine (15 mM) for 4
Securinine Induces AML Differentiation
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21203
Interestingly, securinine’s GABA activity does not appear to be
involved in its AML differentiation activity suggesting that
securinine can be further modified as an AML therapeutic to
minimize its potential for causing seizures. Work is currently in
progress to identify securinine analogues that have this desired
activity. Overall, these studies demonstrate that securinine’s
potential as an AML therapeutic and identify novel mechanisms
of action of this compound that lead to its activity as a
differentiation agent.
Materials and Methods
Ethics
The Case Western Reserve University Animal Research
Committee approved all of the animal protocols used in this study.
Chemicals
1,25 dihydroxyvitamin D3, ATRA, Nitroblue tetrazolium
(NBT), UCN01 and PMA were purchased from Sigma. Securinine
was purchased from LKT Labs. Bisindolylmaleimide (BIS) was
from Calbiochem.
Cell Lines
All cell lines were obtained from ATCC except OCI-AML3
cells were from DSMZ and YAMC cells were provided by Dr.
Sandy Markowitz. Patient samples were obtained from the stem
cell core facility at University Hospitals Case Medical Center.
Cells were cultured in IMDM or RPMI-1640 media (Invitro-
gen) except for HCT116, 293T (DMEM) and HUVEC (EGM
Lonza). Media was supplemented with 10% FBS (Invitrogen),
penicillin G (100 mg/ml) and streptomycin (100 mg/ml). Mono-
nuclear cells were separated by Ficoll-Hypaque (Sigma) density-
gradient centrifugation and for selected patients leukemic
myeloblasts were isolated by flow sorting after staining with anti-
CD34 PE (Beckton Dickinson). The work on human primary cells
was approved by the IRB at the Case Western Reserve University
Cancer Center.
Compound Library Screen
For screening, HL-60 cells (56105 cells/ml) were cultured in 96-
well plates. Cells were treated with 10 mM of compounds from the
Prestwick collection (Prestwick). DMSO (0.1%) and ATRA (1 mM)
were used as negative and positive controls respectively. After 5
days the differentiation of the cells was assessed by the nitroblue
tetrazolium (NBT) reduction assay. To perform the NBT assay,
20 ml of a solution of NBT (5 mg/ml) and PMA 200 ng/ml (as a
stimulant of the respiratory burst) was added to the HL-60 cells.
The cells were incubated at 37uC for 30–40 minutes and the color
of the wells was assessed. Those wells that displayed a visual color
change from the production of blue insoluble formazan greater
than the negative control where examined microscopically to
determine the percentage of blue cells. At least 200 cells were
counted for each positive well.
Differentiation
NBT reduction was performed in a similar manner as described
for the compound library screen. Immunophenotyping was
performed by co-staining cells with CD11b-PE and CD14-FITC
(Beckton Dickinson). The stained samples were run on a Beckman
Coulter Cytomics FC 500 cytometer. For morphology assessment,
cytospin preparations were made using a Shandon cytospin3
cytocentrifuge and the slides were stained with a modified wright-
giemsa stain. For the combination drug studies, the Bliss synergy
method was utilized to confirm the combination treatments led to
synergistic differentiation.
Cell proliferation and viability
Cell proliferation was assessed by manual counting at least 200
cells in 2 separate fields with a hematocytometer as well as with a
Coulter counter. Cell viability was assessed by the trypan blue dye
exclusion method.
Clonogenic assays
Cells were treated with securinine or vehicle for 4 days. The
cells were washed twice with PBS and 10000 viable THP-1, OCI-
AML3 or HL-60 cells were dissolved in 3 ml of 0.30–0.35% Soft
Agar (Noble Agar, Sigma) supplemented with 20% FBS. The cells
were plated in gridded plates and incubated for 10 days in 37uC in
a 5% CO2 incubator. After 10 days the colonies were counted
under a light microscope. A minimum of 20 cells was required to
be considered a colony. For the primary patient samples and
normal human bone marrow cells, the cells were dissolved in
methylcellulose supplemented with 20% FBS, SCF, G-CSF, GM-
CSF and IL-3.
Cell cycle analysis
Cells were treated for 24 hours and fixed at 220uC in 90%
methanol. Cells were washed in PBS, treated with RNase A (final
concentration 0.5 mg/ml) (Sigma) and stained with propidium
iodide (50 mg/ml). The cells were kept at RT for 30–60 minutes
and analyzed by flow cytometry.
Gene Expression Array
HL-60 cells were treated with securinine (15 mM) for 24 hours,
total RNA was isolated and cRNA was prepared using the
Illumina Totalprep RNA amplification kit (Ambion). The cRNA
was assessed with a Human-Ref-8 Illumina expression array and
the data was analyzed using the Bead Studio Software (Illumina).
Analysis was performed to identify genes that underwent at least a
2.5 fold change in expression and that had a known function in
transcription using the Bead Studio Software.
Real-Time PCR
Total RNA was isolated from cells treated with securinine or
vehicle at indicated time points, using TRIzol reagent (Invitrogen).
RNA was transcribed into cDNA using the Enhanced Avian RT
First Strand Synthesis Kit (Sigma). Relative quantitative PCR was
performed in triplicate using the FastStart SYBR Green Master
(Roche Diagnostics) on an Applied Biosystems 7500 Fast Real-
TimePCR System (see Figure S1 for primers and thermal
conditions).
Western blot analysis
Western blot analysis was performed with p21, p53, p-H2AX
(Santa Cruz), p-Chk1 (Cell Signaling) and b-actin antibodies
(Sigma). Cells were treated with securinine or vehicle for the
indicated times and washed in PBS. Cells were centrifuged and
days and the NBT reduction assay and CD11b expression was assessed. C. p21 impairs securinine-mediated growth arrest but not securinine-
mediated differentiation. OCI-AML3 cells stably infected with shp21 or vector control were treated with the indicated doses of securinine and were
counted after 72 hr using a Coulter Counter.
doi:10.1371/journal.pone.0021203.g005
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lysed with a Triton containing lysis buffer. Protein lysates (50 mg
per lane) were electrophoresed on SDS-polyacrylamide gels and
then transferred to PVDF membranes (Millipore) using a wet
transfer apparatus (Bio-Rad). The membranes were blocked,
incubated with the indicated primary antibodies at 4uC overnight,
and then the appropriate HRP conjugated secondary antibody.
Protein bands were visualized by autoradiography after incubation
with enhanced chemiluminescence reagent (Pierce).
Lentiviral infection
Lentiviruses for shp21, shp53, shChk1 (Sigma) and the empty
lentiviral vector, pLKO.1 (Open Biosystems) were packaged in
293T cells using packaging constructs pCMV-dR8.74 and
pMD2G (Addgene). The shp21 and shp53 constructs were kindly
provided by Dr. Mark Jackson. Supernatant media containing
virus, collected at 48 h was concentrated 20 fold by precipitation
with PEG overnight and supplemented with 4 mg/mL polybrene.
OCI-AML3 cells were infected with virus containing media for
24 hours and then selected for stable infection with puromycin
(1 mg/ml). Knockdown was confirmed by western blot (see Figure
S3).
Mouse Xenograft
6 week old female nude mice were injected bilaterally s.c. with
106106 HL-60 cells. Drug treatment was started 10 days after
tumor cell injection. Palpable tumors were present for the
established tumor model prior to initiating drug treatment.
15 mg/kg of securinine or vehicle (30 mL of DMSO and 70 ml
of water ) were injected i.p. 2 or 3 times a day for 5 days followed
by once a day for two days. This injection schedule was repeated
for two additional weeks. The Case Western Reserve University
Animal Research Committee approved all of the animal protocols
used in this study.
Supporting Information
Figure S1 Real-time PCR primers and thermal condi-
tions.
(TIFF)
Figure S2 Transcription-related genes exhibiting a 2.5
fold or greater change in expression after securinine
treatment.
(DOCX)
Figure S3 OCI-AML3 cells exhibiting knockdown of
Chk1, p53 and p21. OCI-AML3 cells infected with a vector
control or the indicated shRNA were lysed and the protein was
analyzed by western blot. As the level of p21 protein expression is
relatively low in the untreated OCI-AML3 cells, these cells were
treated with doxorubicin to induce p21 expression.
(TIFF)
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